NK cells derived from genetically engineered human induced pluripotent stem cells (iPSCs) hold great potential to become the next generation allogeneic cell therapy products.

Qihan Biotech Co. Ltd announced today that it has raised an additional $67 million in Series A++ financing. With these investments, Qihan’s total Series A financing raised to date has exceeded $100 million.

In a leap forward for immune privileged cell and organ therapy, researchers create first clinical xenotransplantation prototype with enhanced human immune compatibility and without active porcine endogenous retrovirus (PERV).